HOWL (Werewolf Therapeutics, Inc.) Stock Financials & Earnings

HOWLWerewolf Therapeutics, Inc.

Mkt Cap$35M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$73M

EPS (TTM)-$1.62

Free Cash Flow (TTM)-$64M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth-100.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$7M	-$6M	-$13M
Q1 23	$4M	$4M	-$12M
Q2 23	$8M	$8M	-$6M
Q3 23	$6M	$5M	-$9M
Q4 23	$2M	$1M	-$13M
Q1 24	$742K	$278K	-$17M
Q2 24	$1M	$689K	-$19M
Q3 24	$0	$0	-$17M
Q4 24	$0	$0	-$20M
Q1 25	$0	-$426K	-$18M
Q2 25	$0	-$406K	-$18M
Q3 25	$0	$0	-$16M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 22	$16M	$3M	$4M
Q1 23	$12M	$5M	—
Q2 23	$10M	$5M	—
Q3 23	$11M	$4M	—
Q4 23	$10M	$5M	—
Q1 24	$13M	$5M	—
Q2 24	$15M	$5M	—
Q3 24	$13M	$5M	—
Q4 24	$16M	$5M	—
Q1 25	$13M	$5M	—
Q2 25	$13M	$4M	—
Q3 25	$12M	$4M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$129M	$0	$129M
Q1 23	$148M	$0	$148M
Q2 23	$137M	$0	$137M
Q3 23	$130M	$0	$130M
Q4 23	$134M	$0	$134M
Q1 24	$139M	$0	$139M
Q2 24	$135M	$0	$135M
Q3 24	$123M	$0	$123M
Q4 24	$111M	$0	$111M
Q1 25	$92M	$0	$92M
Q2 25	$78M	$0	$78M
Q3 25	$66M	$0	$66M

Shares Outstanding

Revenue Per Employee

Revenue / Employee